Stereotactic Ablative Radiation Therapy for Lung Tumors Using Helical Tomotherapy: A Cost-effective Treatment Regimen

Abstract

Stereotactic ablative radiation therapy (SABR) has been shown to be a highly efficacious approach in medically inoperable early-stage lung cancer as well as oligometastatic disease. There is limited data regarding the costs of such approaches in comparison to standard fractionated radiation therapy treatments or surgery. We sought to evaluate our SABR program looking at efficacy of treatment , treatment related toxicity, and costs of SABR versus alternative approaches including standard fractionated radiation therapy and surgery.